| 1 |
Cancer therapeutics using survivin BIRC5 as a target: what can we do after over two decades of study?
Fengzhi Li, Ieman A. M. Aljahdali, Xiang Ling · Journal of Experimental & Clinical Cancer Research
Open access |
22 Aug 2019 |
271 |
| 2 |
Camptothecin (CPT) and its derivatives are known to target topoisomerase I (Top1) as their mechanism of action: did we miss something in CPT analogue molecular targets for treating human disease such as cancer?
Fengzhi Li, Tao Jiang, Qingyong Li et al. · PubMed
Open access |
2017 |
226 |
| 3 |
Kidney cancer biomarkers and targets for therapeutics: survivin (BIRC5), XIAP, MCL-1, HIF1α, HIF2α, NRF2, MDM2, MDM4, p53, KRAS and AKT in renal cell carcinoma
Fengzhi Li, Ieman A. M. Aljahdali, Renyuan Zhang et al. · Journal of Experimental & Clinical Cancer Research
Open access |
12 Aug 2021 |
114 |
| 4 |
FL118, a novel camptothecin derivative, is insensitive to ABCG2 expression and shows improved efficacy in comparison with irinotecan in colon and lung cancer models with ABCG2-induced resistance
David Westover, Xiang Ling, Hong Lam et al. · Molecular Cancer
Open access |
23 Apr 2015 |
74 |
| 5 |
An ABCG2 non-substrate anticancer agent FL118 targets drug-resistant cancer stem-like cells and overcomes treatment resistance of human pancreatic cancer
Xiang Ling, Wenjie Wu, Chuandong Fan et al. · Journal of Experimental & Clinical Cancer Research
Open access |
Oct 2018 |
68 |
| 6 |
Role of the DEAD-box RNA helicase DDX5 (p68) in cancer DNA repair, immune suppression, cancer metabolic control, virus infection promotion, and human microbiome (microbiota) negative influence
Fengzhi Li, Xiang Ling, Sayan Chakraborty et al. · Journal of Experimental & Clinical Cancer Research
Open access |
18 Aug 2023 |
48 |
| 7 |
FL118, acting as a ‘molecular glue degrader’, binds to, dephosphorylates and degrades the oncoprotein DDX5 (p68) to control c‐Myc, survivin and mutant Kras against colorectal and pancreatic cancer with high efficacy
Xiang Ling, Wenjie Wu, Ieman A. M. Aljahdali et al. · Clinical and Translational Medicine
Open access |
May 2022 |
40 |
| 8 |
FL118, a novel camptothecin analogue, overcomes irinotecan and topotecan resistance in human tumor xenograft models.
Xiang Ling, Xiaojun Liu, Kai Long Zhong et al. · PubMed
Open access |
2015 |
40 |
| 9 |
Molecular Glues: Capable Protein-Binding Small Molecules That Can Change Protein–Protein Interactions and Interactomes for the Potential Treatment of Human Cancer and Neurodegenerative Diseases
Fengzhi Li, Ieman A. M. Aljahdali, Xiang Ling · International Journal of Molecular Sciences
Open access |
Jun 2022 |
38 |
| 10 |
Multiple functions of the DEAD-box RNA helicase, DDX5 (p68), make DDX5 a superior oncogenic biomarker and target for targeted cancer therapy.
Fengzhi Li, Christos K Fountzilas, Igor J. Puzanov et al. · PubMed
Open access |
2021 |
22 |
| 11 |
Mutant Kras as a Biomarker Plays a Favorable Role in FL118-Induced Apoptosis, Reactive Oxygen Species (ROS) Production and Modulation of Survivin, Mcl-1 and XIAP in Human Bladder Cancer
Sreevidya Santha, Xiang Ling, Ieman A. M. Aljahdali et al. · Cancers
Open access |
18 Nov 2020 |
22 |
| 12 |
Structure–Activity Relationship of FL118 Platform Position 7 Versus Position 9-Derived Compounds and Their Mechanism of Action and Antitumor Activity
Wenchao Wang, Xiang Ling, Ruojiong Wang et al. · Journal of Medicinal Chemistry
Open access |
15 Dec 2023 |
11 |
| 13 |
Single protein encapsulated SN38 for tumor-targeting treatment
Changjun Yu, Faqing Huang, Kinsley Wang et al. · Journal of Translational Medicine
Open access |
10 Dec 2023 |
11 |
| 14 |
Kras mutation subtypes distinctly affect colorectal cancer cell sensitivity to FL118, a novel inhibitor of survivin, Mcl-1, XIAP, cIAP2 and MdmX.
Thangaiyan Rabi, Ieman A. M. Aljahdali, Kelsey Y Lent-Moore et al. · PubMed
Open access |
2021 |
8 |
| 15 |
Clinically and orally compatible formulation-manufactured DDX5 (p68)-targeting molecular glue FL118 products exhibit low toxicity but high efficacy against human cancer
Xiang Ling, Wenjie Wu, Li Yan et al. · Journal of Pharmaceutical Analysis
Open access |
13 May 2024 |
7 |
| 16 |
FL496, an FL118-derived small molecule, induces growth inhibition, senescence, and apoptosis of malignant pleural mesothelioma (MPM) cells, and exhibits anti-MPM tumor efficacy strikingly superior to the pemetrexed-cisplatin combination
Ieman A. M. Aljahdali, Xiang Ling, Wenjie Wu et al. · Journal of Experimental & Clinical Cancer Research
Open access |
21 Oct 2025 |
2 |
| 17 |
Targeted Treatment of Sarcomas by Single Protein Encapsulated Doxorubicin with Undetectable Cardiotoxicity and Superior Efficacy
Changjun Yu, Faqing Huang, Leslie Wang et al. · Cancers
Open access |
4 Mar 2025 |
2 |
| 18 |
Additional file 1 of DDX5 (p68) and UbE2T as emerging superior cancer therapeutic targets: dual molecular glue target degradation by FL118 for conquering difficult-to-treat cancers
Fengzhi Li, Xiang Ling, Sayan Chakraborty et al. · Figshare
Open access |
18 May 2026 |
0 |
| 19 |
DDX5 (p68) and UbE2T as emerging superior cancer therapeutic targets: dual molecular glue target degradation by FL118 for conquering difficult-to-treat cancers
Fengzhi Li, Xiang Ling, Sayan Chakraborty et al. · Journal of Experimental & Clinical Cancer Research
Open access |
18 May 2026 |
0 |
| 20 |
Synthesis and biological evaluation of 20(S)-substituted FL118 conjugates as novel antitumor agents
Jiewei Lai, Mengke Wang, Weitong Hu et al. · Journal of Molecular Structure
Open access |
7 Jul 2022 |
0 |